Лепра

Список литературы

Основные статьи

World Health Organization Action Programme for the Elimination of Leprosy. A guide to eliminating leprosy as a public health problem. 2nd ed. Geneva: World Health Organization; 1997. WHO/LEP/97.7.

World Health Organization. Implementation of MDT. In: Multidrug therapy against leprosy: Development and implementation over the past 25 years. Geneva: World Health Organization; 2004:45-68. Полный текст

World Health Organization. Guidelines for the diagnosis, treatment and prevention of leprosy. Oct 2018 [internet publication].Полный текст

WHO Expert Committee on Leprosy. 8th report. World Health Organ Tech Rep Ser. 2012;968:1-61.Полный текст  Аннотация

Статьи, указанные как источники

1. World Health Organization Action Programme for the Elimination of Leprosy. A guide to eliminating leprosy as a public health problem. 2nd ed. Geneva: World Health Organization; 1997. WHO/LEP/97.7.

2. Ridley DS Jopling.WH. Classification of leprosy according to immunity: a five-group system. Int J Lepr Other Mycobact Dis. 1966 Jul-Sep;34(3):255-73. Аннотация

3. World Health Organization. Implementation of MDT. In: Multidrug therapy against leprosy: Development and implementation over the past 25 years. Geneva: World Health Organization; 2004:45-68. Полный текст

4. Han XY, Jessurun J. Severe leprosy reactions due to Mycobacterium lepromatosis. Am J Med Sci. 2013;345:65-9.Полный текст  Аннотация

5. Kamath S, Vaccaro SA, Rea TH, et al. Recognizing and managing the immunologic reactions in leprosy. J Am Acad Dermatol. 2014;71:795-803. Аннотация

6. World Health Organization - Global Leprosy Programme. Global leprosy strategy 2016-2020: accelerating towards a leprosy-free world. 2016 [internet publication].Полный текст

7. Fulton N, Anderson LF, Watson JM, et al. Leprosy in England and Wales 1953-2012: surveillance and challenges in low incidence countries. BMJ Open. 2016 May 3;6(5):e010608.Полный текст  Аннотация

8. Cole ST, Eiglmeier K, Parkhill J, et al. Massive gene decay in the leprosy bacillus. Nature. 2001;409:1007-1011.Полный текст  Аннотация

9. Han XY, Sizer KC, Tan HH. Identification of the leprosy agent Mycobacterium lepromatosis in Singapore. J Drugs Dermatol. 2012;11:168-172. Аннотация

10. Scollard DM, Adams LB, Gillis TP, et al. The continuing challenges of leprosy. Clin Microbiol Rev. 2006;19:338-381.Полный текст  Аннотация

11. Rees RJ, McDougall AC. Airborne infection with Mycobacterium leprae in mice. J Med Microbiol. 1977;10:63-68. Аннотация

12. Chehl S, Job CK, Hastings RC. Transmission of leprosy in nude mice. Am J Trop Med Hyg. 1985;34:1161-1166. Аннотация

13. Truman RW, Singh P, Sharma R, et al. Probable zoonotic leprosy in the southern United States. N Engl J Med. 2011;364:1626-1633.Полный текст  Аннотация

14. Avanzi C, Del-Pozo J, Benjak A, et al. Red squirrels in the British Isles are infected with leprosy bacilli. Science. 2016 Nov 11;354(6313):744-47. Аннотация

15. Yamamura M, Uyemura K, Deans RJ, et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science. 1991;254:277-279. Аннотация

16. Mira MT, Alcaïs A, Nguyen VT, et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature. 2004;427:636-640. Аннотация

17. Misch EA, Berrington WR, Vary JC Jr, et al. Leprosy and the human genome. Microbiol Mol Biol Rev. 2010;74:589-620.Полный текст  Аннотация

18. Guinto RS, Rodriguez JN, Doull JA, et al. The trend of leprosy in Cordova and Talisay, Cebu Province, Philipines. Int J Lepr. 1954;22:409-430. Аннотация

19. Noordeen SK, Neelan PN. Extended studies on chemoprophylaxis against leprosy. Indian J Med Res. 1978;67:515-527. Аннотация

20. Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet. 1996;348:17-24. Аннотация

21. Convit J, Sampson C, Zuniga M, et al. Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results. Lancet. 1992;339:446-450. Аннотация

22. Gupte MD, Vallishayee RS, Anantharaman DS, et al. Comparative leprosy vaccine trial in south India. Indian J Lepr. 1998;70:369-388. Аннотация

23. Setia MS, Steinmaus C, Ho CS, et al. The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect Dis. 2006;6:162-170. Аннотация

24. Zodpey SP. Protective effect of bacillus Calmette Guerin (BCG) vaccine in the prevention of leprosy: a meta-analysis. Indian J Dermatol Venereol Leprol. 2007;73:86-93. Аннотация

25. Zodpey SP. The BCG controversy: a reappraisal of the protective effect against tuberculosis and leprosy. Indian J Public Health. 2004;48:70-77. Аннотация

26. Kartikeyan S, Chaturvedi RM, Deo MG. Anti-leprosy vaccines: current status and future prospects. J Postgrad Med. 1991;37:198-204.Полный текст  Аннотация

27. Montestruc E, Berdonneau R. Two cases of leprosy in infants in Martinique [in French]. Bull Soc Pathol Exot Filiales. 1954;47:781-783. Аннотация

28. World Health Organization. Guidelines for the diagnosis, treatment and prevention of leprosy. Oct 2018 [internet publication].Полный текст

29. Lazo-Porras M, Prutsky GJ, Barrionuevo P, et al. World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis. BMC Infect Dis. 2020 Jan 20;20(1):62.Полный текст  Аннотация

30. European Medicines Agency. Quinolone- and fluoroquinolone-containing medicinal products. Mar 2019 [internet publication].Полный текст

31. US Food and Drug Administration. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. Dec 2018 [internet publication].Полный текст

32. US Food and Drug Administration. FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. Oct 2018 [internet publication].Полный текст

33. Liu H, Wang Z, Bao F, et al. Evaluation of prospective HLA-B*13:01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy. JAMA Dermatol. 2019 Jun 1;155(6):666-72.Полный текст  Аннотация

34. Van Veen NH, Nicholls PG, Smith WC, et al. Corticosteroids for treating nerve damage in leprosy. Cochrane Database Syst Rev. 2016 May 23;(5):CD005491.Полный текст  Аннотация

35. WHO Expert Committee on Leprosy. 7th report. World Health Organ Tech Rep Ser. 1998;874:20.Полный текст  Аннотация

36. Manickam P, Nagaraju B, Selvaraj V, et al; Team of Study Investigators. Efficacy of single-dose chemotherapy (rifampicin, oflaxacin and minocycline-ROM) in PB leprosy patients with 2 to 5 skin lesions, India: randomised double-blind trial. Indian J Lepr. 2012;84:195-207. Аннотация

37. Cunha Mda G, Virmond M, Schettini AP, et al. OFLOXACIN multicentre trial in MB leprosy FUAM-Manaus and ILSL-Bauru, Brazil. Lepr Rev. 2012;83:261-268. Аннотация

38. International Leprosy Association. Report of the International Leprosy Association Technical Forum: Paris, France, 22-28 February 2002. Int J Lepr Other Mycobact Dis. 2002;70(suppl):S1-S62. Аннотация

39. Consigny S, Bentoucha A, Bonnafous P, et al. Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice. Antimicrob Agents Chemother. 2000;44:2919-2921.Полный текст  Аннотация

40. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307:223-227. Аннотация

41. WHO Expert Committee on Leprosy. 8th report. World Health Organ Tech Rep Ser. 2012;968:1-61.Полный текст  Аннотация

42. International Federation of Anti-Leprosy Associations. ILEP learning guide 4: how to prevent disability in leprosy. 2006 [internet publication].Полный текст

Использование этого контента попадает под действие нашего заявления об отказе от ответственности